Ivacaftor/lumacaftor and Alcohol/Food Interactions
There are 2 alcohol/food/lifestyle interactions with ivacaftor / lumacaftor.
Ivacaftor Food
Moderate Food Interaction
GENERALLY AVOID: Grapefruit juice may increase the plasma concentrations of ivacaftor. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit. Elexacaftor and tezacaftor are also CYP450 3A4 substrates in vitro and may interact similarly with grapefruit juice, whereas lumacaftor is not expected to interact.
ADJUST DOSING INTERVAL: According to prescribing information, systemic exposure to ivacaftor increased approximately 2.5- to 4-fold, systemic exposure to elexacaftor increased approximately 1.9- to 2.5-fold, and systemic exposure to lumacaftor increased approximately 2-fold following administration with fat-containing foods relative to administration in a fasting state. Tezacaftor exposure is not significantly affected by administration of fat-containing foods.
MANAGEMENT: Patients treated with ivacaftor-containing medications should avoid consumption of grapefruit juice and any food that contains grapefruit or Seville oranges. All ivacaftor-containing medications should be administered with fat-containing foods such as eggs, avocados, nuts, meat, butter, peanut butter, cheese pizza, and whole-milk dairy products. A typical cystic fibrosis diet will satisfy this requirement.
References (4)
- (2012) "Product Information. Kalydeco (ivacaftor)." Vertex Pharmaceuticals
- (2015) "Product Information. Orkambi (ivacaftor-lumacaftor)." Vertex Pharmaceuticals
- (2022) "Product Information. Symdeko (ivacaftor-tezacaftor)." Vertex Pharmaceuticals
- (2019) "Product Information. Trikafta (elexacaftor/ivacaftor/tezacaftor)." Vertex Pharmaceuticals
Switch to consumer interaction data
Ivacaftor High Blood Pressure (Hypertension)
Moderate Potential Hazard, Moderate plausibility
ivacaftor - hypertension
The use of products containing ivacaftor is associated with an increase in blood pressure. Close monitoring of blood pressure is recommended periodically in all patients, in particular in hypertensive patients.
References (2)
- (2023) "Product Information. Orkambi (ivacaftor-lumacaftor)." Vertex Pharmaceuticals
- (2023) "Product Information. Kalydeco (ivacaftor)." Vertex Pharmaceuticals, SUPPL-40
Switch to consumer interaction data
Ivacaftor/lumacaftor drug interactions
There are 572 drug interactions with ivacaftor / lumacaftor.
Ivacaftor/lumacaftor disease interactions
There are 6 disease interactions with ivacaftor / lumacaftor which include:
More about ivacaftor / lumacaftor
- ivacaftor/lumacaftor consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: CFTR combinations
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.